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WS6.5 Body mass index, carbohydrate intake and insulin dosage per
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Objectives: Secondary diabetes becomes more prevalent in CF. However, research on CF-related
diabetes (CFRD) is still rare. We analyzed BMI, carbohydrate intake and insulin requirement per
carbohydrate unit (1 CU equals 11g carbohydrates) in CFRD.
Methods: Until March 2013, the multicenter, prospective German/Austrian diabetes patient registry
(DPV) comprised anonymized data on 208 insulin-treated CFRD patients (63% female) with age
>5 years at diabetes onset and without tube feeding, lung transplantation or systemic steroid therapy.
Median age (IQR) was 18.3 (5.7) years for females and 18.9 (4.3) years for males. Gender-speciﬁc
analyses were carried out. To compare hemoglobin A1c (HbA1c), carbohydrate intake and insulin
requirement per CU, hierarchic multivariable regression models were applied. All analyses were done
with SAS 9.4.
Results: 80.0% of females and 80.3% of males did not achieve gender- and age-speciﬁc ADA
recommendations for BMI (Moran et al., 2010). Based on WHO criteria, 34.6% of females and
39.5% of males had a BMI <18.5 kg/m2. Using the 10th BMI-percentile, 32.3% of females and
39.5% of males were underweight. After adjustment for age, males had a higher carbohydrate intake
than females (254±11 vs. 219±9g, p = 0.012). Metabolic control assessed by HbA1c (females vs.
males: 7.6±0.2 vs. 7.9±0.2%) and insulin requirement per CU (1.33±0.09 vs. 1.23±0.11 IU/CU*d)
did not differ signiﬁcantly between genders.
Conclusion: About one third of insulin-treated CFRD patients revealed a poor nutritional status.
Despite a higher carbohydrate intake in males, no gender difference was observed for insulin
requirement per carbohydrate unit.
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Objectives: The diagnosis of CF related diabetes (CFRD) is traditionally by WHO
criteria with acknowledgement that they are not ideal for CF. Continuous glucose
monitoring (CGM) is used as a diagnostic tool in this unit as well as OGTT. CGM
gives a measure of % time above the upper limit of normal for glucose (7.8mmol/L),
as well as capturing peaks of glucose over the DM diagnostic cut off of 11.1.
Aims: To compare glycaemic and clinical parameters of children whose CGM
resulted in starting insulin therapy to those whose did not. All were screened
for CFRD on clinical suspicion (poor wt, unexplained deterioration, high random
glucose) or raised HbA1c.
Methods: A retrospective audit of CGM data (iPro2) obtained on CF children
2010−13 at the Royal Brompton Hospital, London.
Results: 44 children screened with CGM (18 male), median age 13.8 yrs (IQ range
12.1–15.2). The median length of recording was 4 days. 15 children were started on
insulin based on CGM results, median age 13 yrs of those who commenced insulin
therapy vs 14 yrs who did not, FEV1 z-score −2.29 vs −1.52, BMI z-score −0.04 vs
−0.8. Percentage time >7.8 was 26% vs 5% (p< 0.001) and time within 3.9−7.8 was
68% vs 89% (p< 0.001). There was no correlation between glucose % time >7.8
and HbA1c although there was a slightly higher proportion with raised HbA1c in
the diagnostic group 8/15 (53%) vs 8/29 (28%) and no signiﬁcant difference in
HbA1c between the two groups 6.3% vs 5.9%.
Conclusion: The combination of CGM results and clinical status is invaluable in
the decision-making process regarding starting insulin within the paediatric CF
population.
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Low bone density is commonly seen in patients with cystic ﬁbrosis (CF) and begins
at a young age. The underlying molecular defect in CFTR caused by the F508del-
CFTR mutation in osteoblastogenesis, i.e., on the bone formation is unknown. We
investigated whether the F508del mutation could affect the expression of osteoblast
genes relative to differentiation [collagen type 1, osteocalcin (OC), osteopon-
tin (ON), alkaline phosphatase (ALPL), RUNX2, OSX] and maturation [BMP2,
SMAD1/2, osteoprotegerin (OPG), receptor activator of NF-úB ligand (RANKL),
cyclooxygenase-2 (COX-2)] in osteoblasts. CF osteoblasts were obtained from bone
explants prepared from rib fragments harvested during lung transplantation in
four young patients with the F508del mutation in CFTR. We showed evidence
of CFTR-dependent chloride activity in normal osteoblasts, which was reduced
in CF osteoblasts. Compared to normal osteoblasts, real time PCR data showed
no difference in differentiation genes in CF osteoblasts. But, a severe defective
maturation of CF osteoblasts was found in four CF patients. CF osteoblasts exhibited
a lower expression of SMAD2, COX-2, but a higher RANKL/OPG ratio. Production
of COX-2 metabolite prostaglandin E2 (PGE2) was reduced by CF osteoblasts.
Treatment with the CFTR correctors (a potentiator VRT-532, a correctorVRT-534)
increased the F508del-CFTR channel activity, ameliorated both the RANKL/OPG
mRNA ratio and COX-2/PGE2 expression and production. The effect of such drugs
on the maturation-related genes of F508del osteoblast and their effects on bone mass
and formation needs to be investigated for treatment of CF bone disease.
Vertex provided funding support and research material.
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Objectives: As patients with cystic ﬁbrosis (PWCF) age, we witness an increase in
other comorbid conditions. Amongst these is acute kidney injury (AKI). We studied
the incidence of AKI in an adult cohort of PWCF.
Methods: Retrospective single-centre observational cohort study of 120 adult
PWCF (aged 18−50 yrs) for the period 01/01/11–31/12/12. Patient records were
interrogated to detect evidence of AKI, as deﬁned by the KDIGO 2012 Clinical
Practice Guideline for Acute Kidney Injury.
Results: 74 (62%) male. Median (IQR) age 27 (21, 31) yrs. At 01/01/11, 13 (11%)
had chronic kidney disease (CKD); none subsequently developed this. 25 (21%)
had cystic ﬁbrosis-related diabetes (CFRD); 5 (4%) subsequently developed this.
10 (8%) had received an organ transplant before 01/11/11; 4 (3%) received a
transplant during the study period. 5 (4%) male patients died.
20 (17%) patients (11 male) experienced 57 individual episodes of AKI. This annual
incidence of ~250,000 cases pmp is >200 times that reported for the general
population. Mean AKI episodes per affected patient was 3, the majority being
graded AKIN Stage 1.
Of the 20 patients experiencing AKI, 6 (30%) had pre-existing CKD; 8 (40%) had
pre-existing CFRD; 7 (35%) had an organ transplant. 48/120 (40%) of patients had
at least one of these three co-morbidities. Although not all of these experienced an
episode of AKI, 75% of all AKI episodes occurred within this sub-group.
Conclusion: AKI incidence is very common in this cohort. A subgroup deﬁned
by 3 risk factors had a 1-in-3 probability of developing AKI over a 2 year period.
Focussing preventative strategies and researching risk in this group would seem
appropriate.
